

FORM 7
MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Myconic Capital Corp. (formerly, Auralite Investments Inc.)**(the “**Issuer**”).

Trading Symbol: **MEDI**

Number of Outstanding Listed Securities: **103,350,086 as of April 30, 2021.**

Date: **May 6, 2021**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is an investment issuer with a diversified portfolio that is focused on emerging companies active in the high-tech, real estate, cannabis, mining and health & wellness sectors.

2. Provide a general overview and discussion of the activities of management.

During the month of April 2021, management’s principal activities consisted of:

- **Entering into an LOI with NY Ketamine Medical Practice (“NY Ketamine”) to acquire all of its issued and outstanding share capital.**
- **The appointment of Adam Deffett as Vice President of Capital Markets & Communications;**
- **The issuance of 16,400 common shares pursuant to a shares for service agreement between an officer of the Issuer and the Issuer;**

- Entering into an LOI with Tristar Wellness LLC (“Tristar”) to acquire 49% of its issued and outstanding share capital.
 - Announcing the completion of the acquisition of all the issued and outstanding equity of Mindscape Ketamine & Infusions Therapy, PLLC (“Mindscape”). As a result, the Issuer made a cash payment of US \$50,000 and issued 94,942 common shares of the Issuer (the “Payment Shares”) to the sole owner of Mindscape. The Payment Shares are subject to a lockup period of twelve months, with one third of the Payment Shares each being released at intervals of four, six, and twelve months following closing;
 - Entering into an LOI with Integrated Rehab and Performance Ltd. (“IRP”) to acquire 100% of its issued and outstanding share capital;
 - Entering into a consulting agreement (the “Agreement”) with Meadowbank Strategic Partners Inc. (“Meadowbank”) for investor relations, capital markets and corporate development advisory services for an initial term of six months;
 - Issuing 375,000 stock options to consultants of the Issuer; and
 - Attending to general administration matters.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

The Issuer did not develop any new products or offer any new services during the month of April 2021.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

No products or services were discontinued during the month of April 2021.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

During the month of April 2021 the Issuer entered into an LOI with NY Ketamine to acquire all of its issued and outstanding share capital. Pursuant to the terms of the LOI, the Issuer will acquire all of the shares of NY Ketamine in exchange for USD \$10,000,000, payable in cash and common shares, along with an additional number of common shares pursuant to achieving certain milestone events. The purchase price will be payable in three tranches collectively equal to USD \$5,000,000 in cash and USD \$5,000,000 in common shares over an 18-month period commencing upon the Issuer completing a financing of at least USD \$10,000,000. The shares issued at each tranche will be subject to an 18-month lock-up period, 25% of which will be released 4 months and 1 day from the respective share payment date; 37.5% of which will be released 12 months from the share payment date; and 37.5% of which will be released 18 months from the share payment date. The common shares will be issued at a price per share equal to the volume weighted average trading price of the Issuer’s shares on the CSE for the 30-day period preceding the issuance, subject to the policies of the CSE and applicable securities laws. All securities issued pursuant to the acquisition shall be subject to a four month and one day hold period. The completion of the acquisition is subject to a number of conditions which include but are not limited to the execution of the share purchase agreement and respective employment agreement(s), applicable lease agreements, any municipal, state, or federal licenses, copies of patents, trademarks, or intellectual property applications, completion of satisfactory due diligence, the delivery and satisfactory review of the financial statements of NY Ketamine, and the approval of the transaction by the boards of directors of each of the Issuer and NY Ketamine.

The Issuer entered into an LOI with Tristar to acquire 49% of its issued and outstanding share capital. Pursuant to the LOI, the Issuer will acquire 49% of the of the shares of Tristar for a net purchase price of USD \$818,300, comprised of (i) US \$523,300 equivalent value in common shares in the Issuer (the “Payment Shares”), (ii) US \$245,000 in cash to reduce existing debt obligations, and (iii) US \$50,000 working capital to be applied to search engine optimization and marketing purposes. The Payment Shares will be subject to a lockup period of 24 months on issuance, with 15% of the Payment Shares released 4 months and 1 day following closing, 40% of the Payment Shares released 12 months following closing and 45% of the Payment Shares released 24 months following the closing of the acquisition as contemplated in the LOI. The completion of the acquisition is subject to a number of conditions which include but are not limited to the execution of a definitive agreement, completion of satisfactory due diligence of Tristar, and the approval of the transaction by the boards of directors of each of the Issuer and Tristar.

The Issuer entered into an LOI with IRP to acquire 100% of its issued and outstanding share capital. Pursuant to the terms of the LOI, the Issuer will acquire 100% of IRP’s issued and outstanding shares in exchange for \$1,000,000, payable in common shares in the capital of the Issuer (the “Consideration Shares”). The Consideration Shares shall be issued on the date that the transaction closes (the “Closing Date”) and shall be subject to a voluntary lockup for a period of 18 months, released to the Vendor as follows: five (5%) percent will be freely tradable on the Closing Date; fifteen and eighty-three hundredths (15.83%) percent released quarterly over six quarters from the Closing Date. Furthermore, the LOI provides for a series of bonuses payable in common shares of MEDI (the “Milestone Shares”) upon IRP successfully reaching certain milestones, as outlined below.

<u>Milestone Description</u>	<u>Deadline</u>	<u>Bonus Payable</u>
<u>Two new IRP clinics opened and operational with at least one registered patient at each clinic</u>	<u>September 30, 2021</u>	<u>200,000 MEDI common shares</u>
<u>Total gross revenue from all IRP clinics meets or exceeds CAD \$2,000,000 for IRP’s 2022 fiscal year</u>	<u>First day of IRP’s 2023 fiscal year</u>	<u>250,000 MEDI common shares</u>
<u>Active studies of wearable physical therapy technology at two or more IRP clinics with a minimum of 20 Canadian Armed Forces veterans as participants</u>		<u>100,000 MEDI common shares</u>
<u>Facilitate or broker one clinical or academic study of the benefits of psychedelic intervention treatments</u>		<u>100,000 MEDI common shares</u>
<u>Referral of 50 patients to internal psychedelic clinics</u>		<u>50,000 MEDI common shares</u>

The Consideration Shares and Milestone Shares shall be issued based on the volume weighted average trading price of the Issuer’s common shares for the 10 days preceding the Closing Date or the date on which the shares are earned, as the case may be. All Milestone Shares will be subject to a mandated trading restriction period of four months and one day following issuance of such shares. As a condition of closing the acquisition, IRP’s current Chief Executive Officer, Steven Inglefield, will remain in his current position on a two-year contract commencing on the Closing Date, with an option to extend at the Company’s election. The executive contract shall additionally contain a standard non-compete clause, the grant of 200,000 stock options of the Issuer, and a 10% cash bonus payable on annual net profit. The completion of the acquisition is subject to terms and conditions which include but are not limited to the execution of a definitive agreement, completion of satisfactory due diligence, the delivery and satisfactory review of the financial statements of IRP, and the approval of the transaction by the boards of directors of each of the Issuer and IRP.

The Issuer entered into an Agreement with Meadowbank for investor relations, capital markets and corporate development advisory services for an initial term of six months (the "Initial Term"), subject to the terms of the Agreement. Certain functions and aspects of the Services provided by Meadowbank are anticipated to include "investor relations activities" under the policies of the CSE and applicable securities laws. Pursuant to the terms of the Agreement, Meadowbank will be paid a minimum cash fee of \$3,500 plus GST, per month, for its Services during the Initial Term.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

No contracts, agreements or financings expired or were terminated during the month of April 2021.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions or dispositions of the Issuer's assets occurred during the preceding month of March 2021.

8. Describe the acquisition of new customers or loss of customers.

N/A.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

N/A.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

The Issuer did not hire, terminate or lay-off any employees during the month of April 2021.

11. Report on any labour disputes and resolutions of those disputes if applicable.

N/A.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Issuer is not a party to any legal proceedings.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

N/A.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	16,400	Issued pursuant to agreement with an officer of the Issuer	N/A
Common Shares	94,292	Pursuant to the acquisition of Midscape Ketamine & Infusions Therapy, PLLC	N/A
Stock Options	375,000	Issuance of stock options to consultants	N/A

15. Provide details of any loans to or by Related Persons.

N/A.

16. Provide details of any changes in directors, officers or committee members.

N/A

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's MD&A for the second quarter ended January 31, 2021 filed on SEDAR on March 19, 2021 under the headings "FINANCIAL INSTRUMENTS", "OTHER RISKS AND UNCERTAINTIES" and "RISKS AND UNCERTAINTIES". The MD&A is available on the Issuer's SEDAR profile at www.sedar.com.

In addition to the trends and risks detailed in the MD&A, COVID-19 is likely to impact the Issuer:

COVID-19

The outbreak of the corona virus pandemic has impacted the Issuer's plans and activities. The Issuer may face disruption to operations, supply chain delays, travel and trade restrictions and impact on economic activity in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or diseases represent a serious threat to maintaining a skilled workforce industry and could be a major health-care challenge for the Issuer. There can be no assurance that the Issuer's personnel will not be impacted by these pandemic diseases and ultimately that the Issuer would see its workforce

productivity reduced or incur increased medical costs/insurance premiums as a result of these health risks. In addition, the COVID-19 pandemic has created a dramatic slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, Government response actions, business closures and business disruptions, can all have an impact on the Issuer's operations and access to capital. There can be no assurance that the Issuer will not be impacted by adverse consequences that may be brought about by the COVID-19 pandemic on global financial markets may reduce resource prices, share prices and financial liquidity and thereby that may severely limit the financing capital available.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: May 6, 2021

Robert Meister

Name of Director or Senior Officer

/s/ Robert Meister

Signature

Director & CEO

Official Capacity

Issuer Details Name of Issuer	For Month End	Date of Report YY/MM/D
Myconic Capital Corp. (formerly, Auralite Investments Inc.)	April 2021	21/05/06
Issuer Address		
340 – 1917 West 4 th Avenue		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, BC, V6J 1M7		(604) 351-6647
Contact Name	Contact Position	Contact Telephone No.
Robert Meister	CEO	((604) 351-6647
Contact Email Address	Web Site Address	
RM@caymus.ca	n/a	